search
Back to results

Tumor-specific T Cells in Lung Cancer

Primary Purpose

Non-small Cell Lung Cancer

Status
Active
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Bone marrow aspiration from the iliac crest
Illinois bone marrow aspiration neddle
Sponsored by
University Hospital Heidelberg
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Non-small Cell Lung Cancer

Eligibility Criteria

18 Years - 79 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Patients with histology proven non-small cell lung cancer or a lesion suspicious of non-small cell lung cancer (lung cancer group)
  • Healthy donors (control group)
  • written informed consent

Exclusion Criteria:

  • Autoimmune disease
  • Patients receiving immunomodulatory drugs, e.g. tacrolimus
  • Prior malignancy
  • Pregnancy

Sites / Locations

  • Division of Thoracic Surgery, Technical University of Munich, Munich, Germany

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Lung cancer group

Control group (healthy donors)

Arm Description

Bone marrow puncture in patients with non-small cell lung cancer

Bone marrow puncture in healthy donors

Outcomes

Primary Outcome Measures

Frequencies of tumor-specific T cells
% of all T cells

Secondary Outcome Measures

Tumor-specific T cells location determined by Enzyme Linked Immuno Spot Assay (ELISPOT) analysis of peripheral blood and bone marrow samples from the same patient
location: peripheral versus bone marrow
Long-term survival
OS

Full Information

First Posted
July 30, 2015
Last Updated
July 30, 2023
Sponsor
University Hospital Heidelberg
Collaborators
German Cancer Research Center, Heidelberg University
search

1. Study Identification

Unique Protocol Identification Number
NCT02515760
Brief Title
Tumor-specific T Cells in Lung Cancer
Official Title
Tumor-specific Effector T Cells in Non-small Cell Lung Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
February 2014 (undefined)
Primary Completion Date
June 2018 (Actual)
Study Completion Date
September 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital Heidelberg
Collaborators
German Cancer Research Center, Heidelberg University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Non-small cell lung cancer is characterized by aggressive growth and treatment resistance. New approaches include immunotherapeutic strategies but spontaneous immune responses against tumor antigens remain unclear. The aim of this study is to characterize localization and frequencies of spontaneously induced memory T cells specific for a panel of tumor-associated antigens in peripheral blood and bone marrow of non-small cell lung cancer patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lung cancer group
Arm Type
Experimental
Arm Description
Bone marrow puncture in patients with non-small cell lung cancer
Arm Title
Control group (healthy donors)
Arm Type
Experimental
Arm Description
Bone marrow puncture in healthy donors
Intervention Type
Procedure
Intervention Name(s)
Bone marrow aspiration from the iliac crest
Intervention Type
Device
Intervention Name(s)
Illinois bone marrow aspiration neddle
Primary Outcome Measure Information:
Title
Frequencies of tumor-specific T cells
Description
% of all T cells
Time Frame
2 weeks postoperative
Secondary Outcome Measure Information:
Title
Tumor-specific T cells location determined by Enzyme Linked Immuno Spot Assay (ELISPOT) analysis of peripheral blood and bone marrow samples from the same patient
Description
location: peripheral versus bone marrow
Time Frame
2 weeks postoperative
Title
Long-term survival
Description
OS
Time Frame
5 years postoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Patients with histology proven non-small cell lung cancer or a lesion suspicious of non-small cell lung cancer (lung cancer group) Healthy donors (control group) written informed consent Exclusion Criteria: Autoimmune disease Patients receiving immunomodulatory drugs, e.g. tacrolimus Prior malignancy Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Seyer Safi, MD, PhD
Organizational Affiliation
Division Thoracic Surgery, Technical University of Munich, Munich, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Division of Thoracic Surgery, Technical University of Munich, Munich, Germany
City
Munich
ZIP/Postal Code
81675
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29617574
Citation
Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787. doi: 10.1164/rccm.201708-1707OC.
Results Reference
background
PubMed Identifier
33255425
Citation
Safi S, Yamauchi Y, Hoffmann H, Weichert W, Jost PJ, Winter H, Muley T, Beckhove P. Circulating Interleukin-4 Is Associated with a Systemic T Cell Response against Tumor-Associated Antigens in Treatment-Naive Patients with Resectable Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Nov 24;12(12):3496. doi: 10.3390/cancers12123496.
Results Reference
result
PubMed Identifier
31741774
Citation
Safi S, Yamauchi Y, Stamova S, Rathinasamy A, Op den Winkel J, Junger S, Bucur M, Umansky L, Warth A, Herpel E, Eichhorn M, Winter H, Hoffmann H, Beckhove P. Bone marrow expands the repertoire of functional T cells targeting tumor-associated antigens in patients with resectable non-small-cell lung cancer. Oncoimmunology. 2019 Oct 23;8(12):e1671762. doi: 10.1080/2162402X.2019.1671762. eCollection 2019.
Results Reference
result
PubMed Identifier
29147626
Citation
Safi S, Yamauchi Y, Rathinasamy A, Stamova S, Eichhorn M, Warth A, Rauch G, Dienemann H, Hoffmann H, Beckhove P. Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. Oncoimmunology. 2017 Sep 8;6(11):e1360458. doi: 10.1080/2162402X.2017.1360458. eCollection 2017.
Results Reference
result

Learn more about this trial

Tumor-specific T Cells in Lung Cancer

We'll reach out to this number within 24 hrs